StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group’s 2016 Disruptive Growth and Healthc...
January 28 2016 - 8:05AM
StemCells, Inc. (Nasdaq:STEM) announced today that management will
make presentations on the Company's programs, pipeline and
operations at two upcoming conferences in February.
The Company will be presenting at the 2016 BIO CEO
Conference on Feb. 8 at 2:30 p.m. Eastern Standard Time at the
Waldorf Astoria in New York City. StemCells, Inc. was recognized as
the most innovative public company participating at the BIO CEO
Conference this year winning the 2016 “Buzz of BIO” in the public
company category.
Management will also be presenting at Source
Capital Group’s 2016 Disruptive Growth and Healthcare Conference on
Feb. 18 at 9:30 a.m. Eastern Standard Time at the Convene
Conference Center, 730 3rd Avenue, in New York City.
A live webcast of the presentation will be
available through the Company's corporate website:
http://www.stemcellsinc.com. Interested parties are encouraged to
connect to the website at least 15 minutes prior to the
presentation to ensure adequate time for any software downloads
that may be necessary. In addition, you may directly access the
webcasts through the following links:
BIO CEO
http://www.veracast.com/webcasts/bio/ceoinvestor2016/94127289855.cfm
Source Capital Group’s 2016 Disruptive Growth and
Healthcare Conference
http://wsw.com/webcast/sourcecap1/stem
A replay will also be accessible for 90 days
through the Company's website.
About StemCells, Inc.
StemCells, Inc. is currently engaged in clinical
development of its HuCNS-SC platform technology (purified human
neural stem cells) as a potential treatment for chronic spinal cord
injury (SCI). The Company's Pathway Study, a Phase II
proof-of-concept trial in cervical SCI is actively enrolling at
twelve sites. Six-month interim data for the first cohort of the
Pathway Study showed the first-ever clinical evidence of a
treatment effect improving both muscle strength and motor function
following cellular transplant in spinal cord injury. Top-line data
from the Company's Phase I/II clinical trial in thoracic SCI showed
measurable gains involving multiple sensory modalities and
segments, including the conversion of two of seven patients
enrolled in the study with complete injuries to incomplete
injuries, post-transplant. The Company has also completed its Phase
I/II clinical trial in geographic atrophy dry age related macular
degeneration. Top-line results from this study show a positive
safety profile and favorable preliminary efficacy data. In a Phase
I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company showed preliminary
evidence of progressive and durable donor-derived myelination by
MRI.
Further information about StemCells, Inc. is
available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text
of this press release constitutes forward-looking statements within
the meaning of the U.S. securities laws, and is subject to the safe
harbors created therein. These forward-looking statements speak
only as of the date of this news release. The Company does not
undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
Such statements reflect management's current views and are based on
certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks and
uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2014 and in its
subsequent reports on Forms 10-Q and 8-K.
CONTACT:
Greg Schiffman, Chief Financial Officer
StemCells, Inc.
(510) 456-4128
Lena Evans
Russo Partners
(212) 845-4262
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024